Irodalom:
1. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, Sharma BC, Sarin SK:. A randomized
controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007 Jan;45(1):97-101.
2. Chan HL, Wang H, Niu J, Chim AM, Sung JJ.: Two-year lamivudine treatment for hepatitis B e antigennegative
chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3):345-53.
3. Dienstag JL, Wei LJ, Xu D, Kreter B.: Cross-study analysis of the relative efficacies of oral antiviral therapies
for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Investig. 2007;27(1):35-49.
4. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG,
Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL: Adefovir Dipivoxil 438
Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up
to 5 years. Gastroenterology. 2006 Dec;131(6):1743-51.
5. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ.: Adding-on versus switching-to adefovir therapy in
lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology. 2007 Feb;45(2):307-13.
6. Hézode C, Chevaliez S, Bouvier-Alias M, Roudot-Thoraval F, Brillet R, Zafrani ES, Dhumeaux D,
Pawlotsky JM.: Efficacy and safety of adefovir dipivoxil 20 mg daily in HBeAg-positive patients with
lamivudine-resistant hepatitis B virus and a suboptimal virological response to adefovir dipivoxil 10 mg
daily. J Hepatol. 2007 May;46(5):791-6.
7. Schiff E, Lai CL, Hadziyannis S, Neuhaus P, Terrault N, Colombo M, Tillmann H, Samuel D, Zeuzem S,
Villeneuve JP, Arterburn S, Borroto-Esoda K, Brosgart C, Chuck S: Adefovir Dipivoxil Study 45
Intrnational Investigators Group. Adefovir dipivoxil for wait-listed and post-liver transplantation patients
with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007 Mar;13(3):349-60.
8. Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, Walsh A, Fang J, Hsu M, Mazzucco C,
Eggers B, Zhang S, Plym M, Klesczewski K, Tenney DJ: Entecavir resistance is rare in nucleoside naïve
patients with hepatitis B. Hepatology. 2006 Dec;44(6):1656-65.
9. Tenney DJ, Rose RE, Baldick CJ, Levine SM, Pokornowski KA, Walsh AW, Fang J, Yu CF, Zhang S,
Mazzucco CE, Eggers B, Hsu M, Plym MJ, Poundstone P, Yang J, Colonno RJ: Two-year assessment of
entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes
depending on the resistance substitutions present. Antimicrob Agents Chemother. 2007 Mar;51(3):902-11.
Gyógyszerek, therápia 487
10. Jain MK, Comanor L, White C, Kipnis P, Elkin C, Leung K, Ocampo A, Attar N, Keiser P, Lee WM:
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated
with response. J Viral Hepat. 2007 Mar;14(3):176-82.
11. Johnson RM, Ristig MB, Overton ET, Lisker-Melman M, Cummings OW, Aberg JA: Safety and tolerability
of sequential pegylated IFN-alpha2a and tenofovir for hepatitis B infection in HIV(+) individuals. HIV
Clin Trials. 2007 May-Jun;8(3):173-81.
12. Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, Han BH, Han JY, Byun KS, Cho M, Lee HJ, Kim TH,
Cho SH, Park JW, Um SH, Hwang SG, Kim YS, Lee YJ, Chon CY, Kim BI, Lee YS, Yang JM, Kim HC,
Hwang JS, Choi SK, Kweon YO, Jeong SH, Lee MS, Choi JY, Kim DG, Kim YS, Lee HY, Yoo K, Yoo HW,
Lee HS: Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in
HBeAg-positive chronic hepatitis B. Hepatology. 2007 May;45(5):1172-8.
13. You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL, Chongsuvivatwong V,
Sriplung H, Geater A, Qiao YW, Wu RX: Efficacy of thymosin alpha-1 and interferon alpha in treatment
of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol. 2006 Nov 7;12(41):6715-21.
14. Chien RN, Lin CY, Yeh CT, Liaw YF: Hepatitis B virus genotype B is associated with better response to
thymosin alpha1 therapy than genotype C. J Viral Hepat. 2006 Dec;13(12):845-50.
15. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers
L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA: 018 Study Group. Treatment of hepatitis
B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med.
2007 Dec 4;147(11):745-54.
16. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y,
Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J: Telbivudine versus lamivudine
in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hepatology. 2007 Dec 13
17. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N,
Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA:
Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med.
2007 Dec 20;357(25):2576-88.
18. Moon YM, Hwang SG, Kim BS, Rim KS, Cho M, Kim DJ, Han JY, Kim YS, Choi HS, Ahn SH: The Efficacy
and Safety of Telbivudine in Korean Patients with Chronic Hepatitis B. Korean J Hepatol. 2007 Dec;
13(4):503-512.
19. Sheldon J, Barreiro P, Vincent V: Novel protease and polymerase inhibitors for the treatment of hepatitis
C virus infection. Expert Opin Investig Drugs. 2007 Aug;16(8):1171-81.
20. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J,
Zeuzem S: SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b
for genotype 1 nonresponders. Gastroenterology. 2007 Apr;132(4):1270-8.
21. Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S:
Antiviral activity of telaprevir (VX-950) and peginterferon alpha-2a in patients with hepatitis C. Hepatology.
2007 Sep;46(3):640-8.
22. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C,
Weegink C, Reesink H, Zeuzem S, Kwong AD: Dynamic hepatitis C virus genotypic and phenotypic
changes in patients treated with the protease inhibitor telaprevir. Gastroenterology. 2007 May;132(5):
1767-77.
23. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S: Telaprevir
and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication
in patients. Hepatology. 2007 Sep;46(3):631-9.
488 Gastro Update 2008
24. Flisiak R, Dumont JM, Crabbé R: Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin
Investig Drugs. 2007 Sep;16(9):1345-54.
25. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M,
Hecht D, Oltersdorf T, Shapiro DA: Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower
aminotransferase activity in patients with chronic hepatitis C. Hepatology. 2007 Aug;46(2):324-9.
26. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC: Oral resiquimod in
chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J
Hepatol. 2007 Aug;47(2):174-82. Epub 2007 May 4.
27. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D,
Li J, Kent JD, Pollack PF: Adalimumab for maintenance of clinical response and remission in patients
with Crohn’s disease: the CHARM trial. Gastroenterology. 2007 Jan;132(1):52-65.
28. Peyrin-Biroulet L, Laclotte C, Bigard MA: Adalimumab maintenance therapy for Crohn’s disease with
intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther. 2007 Mar 15;
25(6):675-80.
29. Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA: Adalimumab induction therapy for ulcerative colitis
with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007 Apr
28;13(16):2328-32.
30. Seiderer J, Brand S, Dambacher J, Pfennig S, Jürgens M, Göke B, Ochsenkühn T: Adalimumab in patients
with Crohn’s disease–safety and efficacy in an open-label single centre study. Aliment Pharmacol Ther.
2007 Apr 1;25(7):787-96.
31. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D’Haens G, Li J, Rosenfeld
MR, Kent JD, Pollack PF: Adalimumab induction therapy for Crohn disease previously treated with
infliximab: a randomized trial. Ann Intern Med. 2007 Jun 19;146(12):829-38.
32. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D,
Kent JD, Bittle B, Li J, Pollack PF: Adalimumab for maintenance treatment of Crohn’s disease: results
of the CLASSIC II trial. Gut. 2007 Sep;56(9):1232-9.
33. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S:
PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J
Med. 2007 Jul 19;357(3):228-38.
34. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R,
Sandborn WJ: PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn’s
disease. N Engl J Med. 2007 Jul 19;357(3):239-50.
35. Gisbert JP, González-Lama Y, Maté J: Systematic review: Infliximab therapy in ulcerative colitis. Aliment
Pharmacol Ther. 2007 Jan 1;25(1):19-37.
36. Gavalas E, Kountouras J, Stergiopoulos C, Zavos C, Gisakis D, Nikolaidis N, Giouleme O, Chatzopoulos
D, Kapetanakis N: Efficacy and safety of infliximab in steroid-dependent ulcerative colitis patients.
Hepatogastroenterology. 2007 Jun;54(76):1074-9.
37. MacDonald JK, McDonald JW: Natalizumab for induction of remission in Crohn’s disease. Cochrane
Database Syst Rev. 2007 Jan 24;(1):CD006097. Update of: Cochrane Database Syst Rev. 2006;3: CD006097.
38. Sands BE, Kozarek R, Spainhour J, Barish CF, Becker S, Goldberg L, Katz S, Goldblum R, Harrigan R,
Hilton D, Hanauer SB: Safety and tolerability of concurrent natalizumab treatment for patients with
Crohn’s disease not in remission while receiving infliximab. Inflamm Bowel Dis. 2007 Jan;13(1):2-11.
39. Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S,
Kugathasan S: International Natalizumab CD305 Trial Group Natalizumab therapy for moderate to severe
Crohn disease in adolescents. J Pediatr Gastroenterol Nutr. 2007 Feb;44(2):185-91.
Gyógyszerek, therápia 489
40. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts
PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ: International Efficacy
of Natalizumab in Crohn’s Disease Response and Remission (ENCORE) Trial Group. Natalizumab for
the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007 May;
132(5):1672-83.
41. Hart AL, Plamondon S, Kamm MA: Topical tacrolimus in the treatment of perianal Crohn’s disease:
exploratory randomized controlled trial. Inflamm Bowel Dis. 2007 Mar;13(3):245-53.
42. Yahav J, Samra Z, Niv Y, Evans CT, Passaro DJ, Dinari G, Shmuely H: Susceptibility-guided vs. empiric
retreatment of Helicobacter pylori infection after treatment failure. Dig Dis Sci. 2006 Dec;51(12):2316-21.
43. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, Hassan C, Bernabucci V, Tampieri A, Morini S:
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized
trial. Ann Intern Med. 2007 Apr 17;146(8):556-63.
44. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM: Levofloxacin- vs. ranitidine bismuth
citrate-containing therapy after H. pylori treatment failure. Helicobacter. 2007 Feb;12(1):68-73.
45. Bago P, Vcev A, Tomic M, Rozankovic M, Marusic M, Bago J: High eradication rate of H. pylori with
moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr. 2007;119(11-12):372-8.
46. Sezgin O, Altintas E, Uçbilek E, Tombak A, Tellioglu B: Low efficacy rate of oxifloxacin-containing
Helicobacter pylori eradication treatment: in an observational study in a Turkish population. Helicobacter.
2007 Oct;12(5):518-22. de Bortoli N, Leonardi G, Ciancia E, Merlo A, Bellini M, Costa F, Mumolo MG,
Ricchiuti A, Cristiani F, Santi S, Rossi M, Marchi S. Helicobacter pylori eradication: a randomized
prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol.
2007 May;102(5):951-6.
47. Chuang CH, Sheu BS, Kao AW, Cheng HC, Huang AH, Yang HB, Wu JJ: Adjuvant effect of vitamin C
on omeprazole-amoxicillin-clarithromycin triple therapy for Helicobacter pylori eradication. Hepato
gastroenterology. 2007 Jan-Feb;54(73):320-4.
48. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW: Efficacy of rifaximin, a nonabsorbed
oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci. 2007 May;333
(5):266-70.
49. Scarpellini E, Gabrielli M, Lauritano CE, Lupascu A, Merra G, Cammarota G, Cazzato IA, Gasbarrini G,
Gasbarrini A: High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. Aliment
Pharmacol Ther. 2007 Apr 1;25(7):781-6.
50. Colecchia A, Vestito A, Pasqui F, Mazzella G, Roda E, Pistoia F, Brandimarte G, Festi D: Efficacy of long
term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated
colonic diverticular disease. World J Gastroenterol. 2007 Jan 14;13(2):264-9.
51. Dupont HL, Jiang ZD, Belkind-Gerson J, Okhuysen PC, Ericsson CD, Ke S, Huang DB, Dupont MW,
Adachi JA, De La Cabada FJ, Taylor DN, Jaini S, Martinez Sandoval F: Treatment of travelers’ diarrhea:
randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol
Hepatol. 2007 Apr;5(4):451-6.
52. Nelson R: Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database
Syst Rev. 2007 Jul 18;(3):CD004610.
53. Nocon M, Labenz J, Jaspersen D, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN:
Long-term treatment of patients with gastro-oesophageal reflux disease in routine care – results from
the ProGERD study. Aliment Pharmacol Ther. 2007 Mar 15;25(6):715-22.
54. Scholten T, Teutsch I, Bohuschke M, Gatz G: Pantoprazole on-demand effectively treats symptoms in
patients with gastro-oesophageal reflux disease. Clin Drug Investig. 2007;27(4):287-96.
490 Gastro Update 2008
55. Glatzel D, Abdel-Qader M, Gatz G, Pfaffenberger B: Pantoprazole 40 mg is as effective as esomeprazole
40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior
regarding the prevention of symptomatic relapse. Digestion. 2006;74(3-4):145-54.
56. Goh KL, Benamouzig R, Sander P, Schwan T: EMANCIPATE. Efficacy of pantoprazole 20 mg daily
compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease:
a randomized, double-blind comparative trial – the EMANCIPATE study. Eur J Gastroenterol Hepatol.
2007 Mar;19(3):205-11.
57. Gralnek IM, Dulai GS, Fennerty MB, Spiegel BM: Esomeprazole versus other proton pump inhibitors
in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006
Dec;4(12):1452-8.
58. Wilder-Smith C, Lind T, Lundin C, Nauclér E, Nilsson-Pieschl C, Röhss K:Acid control with esomeprazole
and lansoprazole: a comparative dose-response study. Scand J Gastroenterol. 2007 Feb;42(2):157-64.
59. Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M, Tanaka S, Nishi N, Chayama K,
Haruma K: Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J
Gastroenterol Hepatol. 2007 Mar;22(3):304-10.
60. Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M, Tanaka S, Chayama K, Haruma K:
Treatment of functional dyspepsia with serotonin agonists: A meta-analysis of randomized controlled
trials. J Gastroenterol Hepatol. 2007 Oct;22(10):1566-70.
61. Fried M, Johanson JF, Gwee KA, Wagner A, Pecher E, Rueegg P: Efficacy of tegaserod in chronic
constipation in men. Am J Gastroenterol. 2007 Feb;102(2):362-70.
62. Harish K, Hazeena K, Thomas V, Kumar S, Jose T, Narayanan P: Effect of tegaserod on colonic transit
time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol.
2007 Aug;22(8):1183-9.
63. Fock KM, Wagner A: Asia Pacific Gastroenterology Group. Safety, tolerability and satisfaction with
tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation. J Gastroenterol
Hepatol. 2007 Aug;22(8):1190-8.
64. Lin SR, Ke MY, Luo JY, Yuan YZ, Wang JY, diTommaso S, Walter V, Huang J: A randomized, double-blind,
placebo-controlled trial assessing the efficacy and safety of tegaserod in patients from China with chronic
constipation. World J Gastroenterol. 2007 Feb 7;13(5):732-9.
65. Di Stefano M, Miceli E, Mazzocchi S, Tana P, Missanelli A, Corazza GR: Effect of tegaserod on rectosigmoid
tonic and phasic activity in constipation-predominant irritable bowel syndrome. Am J Gastroenterol.
2007 Aug;102(8):1720-6.
66. Majewski M, Jaworski T, Sarosiek I, Sostarich S, Roeser K, Edlavitch SA, Kralstein J, Wallner G,
McCallum RW, Sarosiek J: Significant enhancement of esophageal pre-epithelial defense by tegaserod:
implications for an esophagoprotective effect. Clin Gastroenterol Hepatol. 2007 Apr;5(4):430-8.
67. Zeng J, Zuo XL, Li YQ, Wei W, Lv GP: Tegaserod for dyspepsia and reflux symptoms in patients with
chronic constipation: an exploratory open-label study. J Clin Pharmacol. 2007 Jun;63(6):529-36.
68. Evangelista S: Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and
gastroesophageal reflux disease. Curr Opin Investig Drugs. 2007 May;8(5):416-22.
69. Di Palma JA, Cleveland MV, McGowan J, Herrera JL: A randomized, multicenter comparison of
polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J
Gastroenterol. 2007 Sep;102(9):1964-71.
70. Di Palma JA, Cleveland MV, McGowan J, Herrera JL: A randomized, multicenter, placebo-controlled
trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol.
2007 Jul;102(7):1436-41. Epub 2007 Mar 31.
Gyógyszerek, therápia 491
71. Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG: A randomized, double-blind,
placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with
severe diarrhea-predominant IBS. Am J Gastroenterol. 2007 Aug;102(8):1709-19.
72. Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD: Effect of a second-generation
alpha2delta ligand (pregabalin) on visceral sensation in hyperszenzitíve patients with irritable bowel
syndrome. Gut. 2007 Sep;56(9):1218-25.
73. Rao SS, Mudipalli RS, Remes-Troche JM, Utech CL, Zimmerman B: Theophylline improves esophageal
chest pain–a randomized, placebo-controlled study. Am J Gastroenterol. 2007 May;102(5):930-8.
